Program
Famotidine
Also written as “Atazanavir+Ritonavir+Tenofovir+Famotidine”, “Famotidine Tablets, 40 mg” and “Atazanavir/Ritonavir + Famotidine”.
Its studies are mostly in COVID-19 · HIV Infections · Ulcer · Arthritis, Juvenile · Heartburn, led by 8 companies.
Drug pageFamotidine: every studyMany companies study it; this page follows only the 13 they lead. All 52 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Leidos Life Sciencesits history only | 30 open or running | phase 2since Oct 7, 2021 | Oct 7, 2021 | none ahead |
| Amgenits history only | 20 open or running | phase 4since Mar 20, 2012 | Mar 19, 2007 | none ahead |
| Perrigoits history only | 20 open or running | phase 1since Dec 3, 2008 | Dec 3, 2008 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Feb 18, 2010 | Feb 18, 2010 | none ahead |
| Astellas Pharmaits history only | 10 open or running | phase 3since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 1since Jan 12, 2012 | Jan 12, 2012 | none ahead |
| drpykessupplements.comits history only | 10 open or running | phase 4since Sep 21, 2020 | Sep 21, 2020 | none ahead |
| Pfizer | 10 open or running | phase 1since Mar 24, 2014 | Mar 24, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2014First study: phase 1 study in HealthyFirst studyNCT02097329 · 27 enrolled · United States
TargetBeta
“Histamine H2 receptor antagonist”ChEMBL 37, by rule
Studies
The one study Pfizer leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02097329Healthy · United States | 1 | Completed | Jun 2014 | 27 |
How it is read
Names in the registry
- “Famotidine”, 8 entries
- “Atazanavir+Ritonavir+Tenofovir+Famotidine”, 4 entries
- “Famotidine Tablets, 40 mg”, 2 entries
- “Atazanavir/Ritonavir + Famotidine”, 2 entries
- “Nirogacestat and Famotidine”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 4 studies
- HIV Infections, 2 studies
- Ulcer, 1 study
- Arthritis, Juvenile, 1 study
- Heartburn, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.